U.S., Aug. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07747090) titled 'A Study of the Efficacy and Safety of FXS6837 Capsules Compared to Eculizumab for 24 Weeks in Patients With PNH.' on July 22.
Brief Summary: An open label study to evaluate the efficacy and safety of FXS6837 capsules compared to eculizumab in naive PNH patients. About 90 PNH patients who are naive to complement inhibitor therapies will be enrolled to take FXS6837 capsules or eculizumab for 24 weeks according to protocol.
Study Start Date: Dec. 10, 2026
Study Type: INTERVENTIONAL
Condition:
Paroxysmal Nocturnal Hemoglobinuria
Intervention:
DRUG: FXS6837 Capsule
FXS6837 capsule orally taken for 24 weeks
BIOLOGICAL: Eculizumab i...